

## Digital Gene Technologies Incorporated

[View the current Digital Gene Technologies Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/3440-Digital+Gene+Technologies+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/3440-Digital+Gene+Technologies+Incorporated.html>)

### Contact Details:

11149 N. Torrey Pines Road Suite 110

La Jolla

CA

92037

United States of America

Tel: 619 552 1400

Fax: 619 552 8625

Email:

### Recent Publications by Digital Gene Technologies Incorporated:



- [Cell culture modeling of specialized tissue: identification of genes expressed specifically by follicle-associated epithelium of Peyer's patch by expression profiling of Caco-2/Raji co-cultures.](#)  
*Peyer's patch follicle-associated epithelium (FAE) regulates intestinal...*3rd August, 2004  
Digital Gene Technologies,- Int Immunol. 2004 Jan;16(1):91-9.
- [Exploiting immune surveillance mechanisms in mucosal vaccine development.](#)  
*Historically, immune responsiveness was regarded by many as an ability to...*14th July, 2004  
Digital Gene Technologies, Inc., 11149 North Torrey Pines Road, Suite- Expert Opin Biol Ther. 2004 Mar;4(3):397-406. ([DOI Direct Link](#))
- [Peptidoglycan recognition protein expression in mouse Peyer's Patch follicle associated epithelium suggests functional specialization.](#)  
*Mammalian Peyer's Patches possess specialized epithelium, the follicle...*6th December, 2003  
Digital Gene Technologies,- Cell Immunol. 2003 Jul;224(1):8-16.
- [Open system gene expression profiling and identification of novel genes for targeted vaccine delivery.](#)  
*Ongoing development of vaccines is limited by the techniques used to...*26th September, 2003  
Digital Gene Technologies,- Expert Rev Vaccines. 2002 Jun;1(1):95-100. ([DOI Direct Link](#))
- [Multiple sclerosis: emerging opportunities for therapeutic intervention.](#)  
*Multiple sclerosis (MS) is a demyelinating disease of the central nervous...*17th June, 2003  
Department of Integrative Biology, Digital Gene Technologies, Inc, 11149- Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):17-30.
- [Catching target receptors for drug and vaccine delivery using TOGA gene expression profiling.](#)  
*Drug delivery technologies are commonly directed towards formulations to...*22nd May, 2003

Digital Gene Technologies, Inc, 11149 North Torrey Pines Road, La Jolla,- Adv Drug Deliv Rev. 2002 Nov 5;54(9):1213-23.

- [Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia.](#)

*Microglial activation is an early and common feature of almost all...* 17th January, 2003

Department of Molecular Biology, The Scripps Research Institute, La Jolla,- J Neurochem. 2002 Dec;83(6):1309-20.

#### Press Releases on Digital Gene Technologies Incorporated:

<a href="#">Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference</a>	24th November, 2009	Quest Diagnostics	MADISON, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is
<a href="#">Prodesse's ProParaflu+(TM) Assay Cleared for US Marketing by FDA</a>	24th November, 2009	Gen-Probe Incorporated	Michael Watts Vice president, investor relations and corporate communications 858-410-8673 SOURCE Gen-Probe Incorporated
<a href="#">Volcano Corporation Presentation at Piper Jaffray Conference to be Webcast</a>	24th November, 2009	Volcano Corporation	SAN DIEGO, Nov. 24 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacture and sales of products for the diagnosis and treatment of coronary and
<a href="#">Aflac To Exchange Two Lloyds Banking Group Securities, Enhance Risk-Based Capital Ratio</a>	24th November, 2009	Aflac Incorporated	COLUMBUS, Ga., Nov. 24 /PRNewswire-FirstCall/ -- Aflac Incorporated (NYSE: AFL) announced today that the Lloyds Banking Group plc has accepted the exchange of two of its investment securities owned by
<a href="#">BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference</a>	24th November, 2009	BioSpecifics Technologies Corp.	LYNBROOK, N.Y., Nov. 24 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

